Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2012

View Archived Issues

MS-275 as a potential therapy for NASH

Veloxis reports preliminary results from STRATO study

Omeros advances lead PDE10 program candidate study

Scancell reports data from first part of phase I/II SCIB-1 trial

DNDi launches pivotal trial of oral drug candidate for African sleeping sickness

Board recommends continuation of phase III ReLive trial

Clinical results reported for OC-000450 in grass pollen allergy

Intradermal injection of HDM-PAD safe and well tolerated in subjects with HDM allergies

Chinese scientists present new histone deacetylase inhibitors

Novel M4 receptor modulators patented by The Vanderbilt University

Scientists at Nerviano Medical Sciences patent new protein kinase inhibitors

Array BioPharma divulges new protein kinase pim inhibitors

Gedeon Richter synthesizes novel MCH1 receptor antagonists

Inovio Pharmaceuticals reports data from trial of its electroporation vaccine delivery system

Abbott designs new GlyT-1 inhibitors

Roche submits line extension application to the EMA for MabThera

Novel TLR4 antagonist demonstrates protective effects in NAFLD

University of Texas MD Anderson and GSK to collaborate on therapeutic antibodies against cancer

FDA advisory committee votes on approval of Zohydro ER

Protalix initiates study of long-term enzyme replacement therapy for Fabry's disease

Isis Pharmaceuticals reports phase I data for three drugs

First patients treated in phase II study of EMA-401

Eleven Biotherapeutics begins phase Ib study in dry eye disease

HM1.24-specific humanized MAb combined with lenalidomide in MM

Clinical studies presented for circularly permuted TRAIL in MM

Biogen Idec and Isis Pharmaceuticals enter global antisense drug collaboration

Tudorza Pressair now available in the U.S.

Pfizer presents phase II data for PD-0332991 plus letrozole

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...